Combination of a novel heat shock protein 90-targeted photodynamic therapy with PD-1/PD-L1 blockade induces potent systemic antitumor efficacy and abscopal effect against breast cancers.
Kensuke KanekoChaitanya R AcharyaHiroshi NagataXiao YangZachary Conrad HartmanAmy HobeikaPhilip F HughesTimothy A J HaysteadMichael A MorseHerbert Kim LyerlyTakuya OsadaPublished in: Journal for immunotherapy of cancer (2022)
The increased antitumor activity and upregulated CXCR3 gene signature induced by the combination of anti-PD-L1 antibody with HS201-PDT warrants the clinical testing of HS201-PDT combined with PD-1/PD-L1 blockade in patients with breast cancer, and the use of the CXCR3 gene signature as a biomarker.